Literature DB >> 1643155

Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome.

E Montefusco1, G Alimena, F Lo Coco, M R De Cuia, Y Z Wang, M A Aloe Spiriti, F Mancini, M Cedrone, M Mancini, F Mandelli.   

Abstract

We report the clinical, hematologic, cytogenetic, and molecular characteristics of 13 patients with Philadelphia-negative (Ph-), bcr-negative atypical chronic myelogenous leukemia (CML). In the majority of cases, the phenotypic features at presentation resembled those of typical CML. However, these patients presented with a higher median age, lower median hemoglobin levels, and lower leukocyte and platelet counts than patients with Ph-positive CML. Cytogenetic analysis showed an abnormal karyotype in only one case. Southern blot investigation, using probes exploring the entire M-bcr region, demonstrated the absence of genomic bcr-abl rearrangements. The assessment of clonality in five patients (study of X-methylation patterns in females heterozygous at the DXS255 locus) indicated the proliferation of a monoclonal cell population. Disease evolution was mostly characterized by bone marrow failure, extramedullary infiltrates, and poor response to chemotherapy, without evidence of overt acute transformation. Our observations suggest that some hematologic and clinical features and the modalities of disease progression are presently the most helpful factors in distinguishing these bcr/abl-negative patients from those with typical bcr+CML. The differences existing also with chronic myelomonocytic leukemia (CMMoL), allow the consideration of ph-/bcr- CML as a separate entity, the nature of which remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643155     DOI: 10.1007/bf01715120

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  19 in total

1.  Diagnosis and classification of the polycythemias.

Authors:  N I Berlin
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

2.  Philadelphia-negative (Ph-) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Français de Cytogénétique Hématologique.

Authors:  P Martiat; J L Michaux; J Rodhain
Journal:  Blood       Date:  1991-07-01       Impact factor: 22.113

3.  Trisomy 14 in atypical chronic myeloid leukemia.

Authors:  F Mertens; B Johansson; S Heim; U Kristoffersson; N Mandahl; I Turesson; C Malm; A Othzén; C R Bartram; D Catovsky
Journal:  Leukemia       Date:  1990-02       Impact factor: 11.528

4.  Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group.

Authors: 
Journal:  Cancer Genet Cytogenet       Date:  1988-05

5.  A highly informative X-chromosome probe, M27 beta, can be used for the determination of tumour clonality.

Authors:  G Abrahamson; N J Fraser; J Boyd; I Craig; J S Wainscoat
Journal:  Br J Haematol       Date:  1990-03       Impact factor: 6.998

6.  bcr rearrangement in Ph-negative CML.

Authors:  C R Bartram; F Carbonell
Journal:  Cancer Genet Cytogenet       Date:  1986-03-15

7.  Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.

Authors:  S Murphy; H Iland; D Rosenthal; J Laszlo
Journal:  Semin Hematol       Date:  1986-07       Impact factor: 3.851

8.  Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.

Authors:  R Kurzrock; H M Kantarjian; M Shtalrid; J U Gutterman; M Talpaz
Journal:  Blood       Date:  1990-01-15       Impact factor: 22.113

Review 9.  Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia.

Authors:  J Laszlo
Journal:  Semin Hematol       Date:  1975-10       Impact factor: 3.851

10.  Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

View more
  2 in total

Review 1.  Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.

Authors:  Andrew T Kuykendall; Eric Padron
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

2.  Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.

Authors:  Huifang Jiang; Zhonglin Wu; L I Ren; Diehong Tao; Hongyan Tong
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.